Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.